Recommendations for the standardisation of oxytocin nasal administration and guidelines for its reporting in human research

Psychoneuroendocrinology

Volumn 38, Issue 5, 2013, Pages 612-625

  Guastella, Adam J ^a   Hickie, Ian B ^a   McGuinness, Margaret M ^a,b   Otis, Melissa ^a,b   Woods, Elizabeth A ^a,d   Disinger, Hannah M ^a,c   Chan, Hak Kim ^a   Chen, Timothy F ^a   Banati, Richard B ^a,e  

^a UNIVERSITY OF SYDNEY   (Australia)

^b BOSTON UNIVERSITY   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d University of Kentucky   (United States)

^e AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION   (Australia)

Author keywords

Absorption; Bioavailability; Blood brain barrier; Clinical trials; Hormone; Human; Methods; Nasal spray; Peptide; Social cognition

Indexed keywords

OXYTOCIN; PENETRATION ENHANCING AGENT;

AEROSOL; ARTICLE; BREATHING; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DELIVERY DEVICE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG SELF ADMINISTRATION; DRUG TRANSPORT; DRUG USE; EQUIPMENT DESIGN; FUNCTIONAL ANATOMY; HEAD POSITION; HUMAN; NOSE; NOSE AIRFLOW; NOSE CAVITY; NOSE MUCOSA; NOSE SEPTUM; PATIENT COMPLIANCE; PATIENT EDUCATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; STANDARDIZATION; VASCULARIZATION;

ADMINISTRATION, INTRANASAL; ADSORPTION; HUMAN EXPERIMENTATION; HUMANS; NASAL SPRAYS; NOSE; OXYTOCIN; PRACTICE GUIDELINES AS TOPIC; RESEARCH DESIGN;

EID: 84876087515     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2012.11.019     Document Type: Article

References (113)

1. Aggarwal R., Cardozo A., Homer J.J. The assessment of topical nasal drug distribution. Clin. Otolaryngol. Allied Sci. 2004, 29:201-205.
2. Andari E., Duhamel J.R., Zalla T., Herbrecht E., Leboyer M., Sirigu A. Promoting social behavior with oxytocin in high-functioning autism spectrum disorders. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:4389-4394.
3. Anderson I., Proctor D.F. Measurement of nasal mucociliary clearance. Eur. J. Resp. Dis. 1983, 64:37-40.
4. Arora P., Sharma S., Garg S. Permeability issues in nasal drug delivery. Drug Discov. Today 2002, 7:967-975.
5. Bahadur S., Pathak K. Physicochemical and physiological considerations for efficient nose-to-brain targeting. Expert Opin. Drug Deliv. 2012, 9:19-31.
6. Bartz J.A., Zaki J., Bolger N., Ochsner K.N. Social effects of oxytocin in humans: Context and person matter. Trends Cogn. Sci. 2011, 15:301-309.
7. Benninger M.S., Hadley J.A., Osguthorpe J.D., Marple B.F., Leopold D.A., Derebery M.J., Hannley M. Techniques of intranasal steroid use. Otolaryngol. Head Neck Surg. 2004, 130:5-24.
8. Bernstein J.A., Davis B.P., Picard J.K., Cooper J.P., Zheng S., Levin L.S. A randomized, double-blind, parallel trial comparing capsaicin nasal spray with placebo in subjects with a significant component of nonallergic rhinitis. Ann. Allergy, Asthma Immunol. 2011, 107:171-178.
9. Born J., Lange T., Kern W., McGregor G.P., Bickel U., Fehm H.L. Sniffing neuropeptides: a transnasal approach to the human brain. Nat. Neurosci. 2002, 5:514-516.
10. Bradfield A. Reservations on the safety of oxytocin nasal spray in obstetrics. Aust. N. Z. J. Obstet. Gynaecol. 1965, 5:138-143.
11. Bryant R.A., Hung L., Guastella A.J., Mitchell P.B. Oxytocin as a moderator of hypnotizability. Psychoneuroendocrinology 2012, 37:162-166.
12. Calhoun K.H., Waggenspack G.A., Simpson C., Hokanson B.J.A., Baily B. CT evaluation of the paranasal sinuses in symptomatic and asymptomatic populations. Otolaryngol. Head Neck Surg. 1991, 104:480-483.
13. Cerkes N. The crooked nose. Aesthet. Surg. J. 2011, 31:241-257.
14. Chandira R.M. Recent Advances of Nasal Drug Delivery Systems 2009, Life Sciences, Farmavita.
15. Chang S.W.C., Barter J.W., Ebitz R.B., Watson K.K., Platt M.L. Inhaled oxytocin amplifies both vicarious reinforcement and self reinforcement in rhesus macaques (Macaca mulatta). Proc. Natl. Acad. Sci. U.S.A. 2012, 109:959-964.
16. Cheng Y.S., Holmes T.D., Gao J., Guilmette R.A., Li S., Surakitbanharn Y., Rowlings C. Characterization of nasal spray pumps and deposition pattern in a replica of the human nasal airway. J. Aerosol. Med. 2001, 14:267-280.
17. Costantino H.R., Illum L., Brandt G., Johnson P.H., Quay S.C. Intranasal delivery: physicochemical and therapeutic aspects. Int. J. Pharm. 2007, 337:1-24.
18. Craft S., Baker L.D., Montine T.J., Minoshima S., Watson G.S., Claxton A., Arbuckle M., Callaghan M., Tsai E., Plymate S.R., Green P.S., Leverenz J., Cross D., Gerton B. Intranasal insulin therapy for alzheimer disease and amnestic mild cognitive impairment. A pilot clinical trial. Arch. Neurol. 2012, 69:29-38.
19. Dahl R., Mygind N. Anatomy, physiology and function of the nasal cavities in health and disease. Adv. Drug Deliv. Rev. 1998, 29:3-12.
20. Dale H.H. The action of extracts of the pituitary body. Biochem. J. 1908, 4:427-447.
21. Dalpiaz A., Paganetto G., Pavan B., Fogagnolo M., Medici A., Beggiato S., Perrone D. Zidovudine and ursodeoxycholic acid conjugation: design of a new prodrug potentially able to bypass the active efflux transport systems of the central nervous system. Mol. Pharm. 2012, 9:957-968.
22. Dalton M.E., Bromham D.R., Ambrose C.L., Osborne J., Dalton K.D. Nasal absorption of progesterone in women. Br. J. Obstet. Gynaecol. 1987, 94:84-88.
23. Dayal P., Shaik M.S., Singh M. Evaluation of different parameters that affect droplet-size distribution from nasal sprays using Malvern Spraytec®. J. Pharm. Sci. 2004, 93:1725-1742.
24. DeSesso J.M. The relevance to humans of animal models for inhalation studies of cancer in the nose and upper airways. Qual. Assur. 1993, 2:213-231.
25. Devender S., Dhanda D.S., Frey W.H., Leopold D., Kompella U.B. Approaches for drug deposition in the human olfactory epithelium. Drug Del. Technol. 2005, 5:64-72.
26. Dhuria S.V., Hanson L.R., Frey W.H. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J. Pharm. Sci. 2010, 99:1654-1673.
27. Doughty D.V., Diao L., Hoag S.W., Dalby R.N. Use of flexible weighted nasal spray dip tubes to improve product performance. J. Aerosol. Med. Pulm. Drug Deliv. 2010, 23:69-75.
28. du Vigneaud V., Ressler C., Swan J.M., Roberts C.W., Katsoyannis P.G. The synthesis of oxytocin. J. Am. Chem. Soc. 1954, 76:3115-3121.
29. Fahmy F.F., McCombe A., Mckiernan D.C. Sino nasal assessment questionnaire, a patient focused, rhinosinusitis specific outcome measure. Rhinology 2002, 40:195-197.
30. Fewtrell M.S., Loh K.L., Blake A., Ridout D.A., Hawdon J. Randomised, double blind trial of oxytocin nasal spray in mothers expressing breast milk for preterm infants. Arch. Dis. Child Fetal. Neonatal. 2006, 91:169-174.
31. Foo M.Y., Cheng Y.S., Su W.C., Donovan M.D. The influence of spray properties on intranasal deposition. J. Aerosol. Med. 2007, 20:495-508.
32. Gao X., Chen J., Tao W., Zhu J., Zhang Q., Chen H., Jiang X. UEA I-bearing nanoparticles for brain delivery following intranasal administration. Int. J. Pharm. 2007, 340:207-215.
33. Garlapati R.R., Lee H.P., Chong F.H., Wang D.Y. Indicators for the correct usage of intranasal medications: A computational fluid dynamics study. Laryngoscope 2009, 119:1975-1982.
34. Ghilzai N.M.K., Desai A. Facing the challenges of transmucosal absorption-buccal, nasal and rectal routes. Pharma Tech. 2004, 104-106.
35. Gimpl G., Fahrenholz F. The oxytocin receptor system: structure, function, and regulation. Physiol. Rev. 2001, 81:629-683.
36. Graf P. Rhinitis medicamentosa: a review of causes and treatment. Treat Respir. Med. 2005, 4:21-29.
37. Grassin-Delyle S., Buenestado A., Naline E., Faisy C., Blouquit-Laye S., Couderc L.-J., Le Guen M., Fischler M., Devillier P. Intranasal drug delivery: An efficient and non-invasive route for systemic administration: Focus on opioids. Pharmacol. Ther. 2012, 134:366-379.
38. Gray L. Deviated nasal septum: incidence and etiology. Ann. Otol. Rhinol. Laryngol. 1980, 87:3-10.
39. Guastella A.J., MacLeod C. A critical review of the influence of oxytocin nasal spray and social cognition: Evidence and future directions. Horm. Behav. 2012, 61:410-418.
40. Guilmette R.A., Cheng Y.S., Griffith W.C. Characterising the variability in adult human nasal airway dimensions. Ann. Occup. Hyg. 1997, 41:491-496.
41. Guo C., Doub W.H. The influence of actuation parameters on in vitro testing of nasal spray products. J. Pharm. Sci. 2006, 95:2029-2040.
42. Guo Y., Laube B., Dalby R. The effect of formulation variables and breathing patterns on the site of nasal deposition in an anatomically correct model. Pharm. Res. 2005, 22:1871-1878.
43. Hadar T., Yaniv E., Shvili Y., Koren R., Shvero J. Histopathological changes of the nasal mucosa induced by smoking. Inhal. Toxicol. 2009, 21:1119-1122.
44. Harris A.S., Ohlin M., Lethagen S., Nilsson I.M. Effects of concentration and volume on nasal bioavailability and biological response to desmopressin. J. Pharm. Sci. 1988, 77:337-339.
45. Hollander E., Bartz J., Chaplin W., Phillips A., Sumner J., Soorya L., Anagnostou E., Wasserman S. Oxytocin increases retention of social cognition in Autism. Biol. Psychiatry 2007, 61:498-503.
46. Iliff J.J., Wang M., Liao Y., Plogg B.A., Peng W., Gundersen G.A., Benveniste H., Vates G.E., Deane R., Goldman S.A., Nagelhus E.A., Nedergaard M. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. Sci. Transl. Med. 2012, 4:147.
47. Inhalation Drug Products Working Group of the Chemistry, M., and Controls Coordinating Committee, 2002. Guidance for industry: Nasal spray and inhalation solution, suspension, and spray drug products - Chemistry, manufacturing, and controls documentation. In: Center for Drug Evaluation and Research, U.S.D.o.H.a.H.S.F.a.D.A. (Ed.). US Governement, Rockville.
48. Inthavong K., Tian Z.F., Li H.F., Tu J.Y., Yang W., Xue C.L., Li C.G. A numerical study of spray particle deposition in a human nasal cavity. Aer. Sci. Tech. 2006, 40:1034-1045.
49. Izdebska K., Ciosek J. Galanin influences on vasopressin and oxytocin release: In vitro studies. Neuropeptides 2010, 44:341-348.
50. Jang Y.J., Myong N.H., Park K.H., Koo T.W., Kim H.G. Mucociliary transport and histologic characteristics of the mucosa of deviated nasal septum. Arch. Otolaryngol. Head Neck Surg. 2002, 128:421-424.
51. Jones A.S., Viani L., Phillips D., Charters P. The objective assessment of nasal patency. Clin. Otolaryngol. Allied Sci. 1991, 16:206-211.
52. Kelly J.T., Asgharian B., Kimbell J.S., Wong B.A. Particle deposition in human nasal airway replicas manufactured by different methods. Part I: Inertial regime particles. Aer. Sci. Tech. 2004, 38:1063-1071.
53. Kemp A.H., Quintana D.H., Kuhnert R.L., Griffiths K., Hickie I.B., Guastella A.J. Oxytocin increases heart rate variability in humans at rest: Implications for social approach-related motivation and capacity for social engagement. PloS One 2012, 7:e44014.
54. Kimbell J.S., Segal R.A., Asgharian B., Wong B.A., Schroeter J.D., Southall J.P., Dickens C.J., Brace G., Miller F.J. Characterization of deposition from nasal spray devices using a computational fluid dynamics model of the human nasal passages. J. Aerosol. Med. 2007, 20:59-74.
55. Kjaergaard T., Cvancarova M., Steinsvåg S.K. Nasal congestion index: a measure for nasal obstruction. Laryngoscope 2009, 119:1628-1632.
56. Korkut A.Y., Islim F., Gulseven C.S., Dogan R., Gedikli O., Kahya V., Gunes G. Evaluation of inferior turbinate hypertrophy in patients with congenital and traumatic nasal septum deviation. J. Laryngol. Otol. 2012, 126:784-788.
57. Kosfeld M., Heinrichs M., Zak P.J., Fischbacher U., Fehr E. Oxytocin increases trust in humans. Nature 2005, 435:673-676.
58. Kundoor V., Dalby R.N. Assessment of nasal spray deposition pattern in a silicone human nose model using a color-based method. Pharm. Res. 2010, 27:30-36.
59. Kundoor V., Dalby R.N. Effect of formulation- and administration-related variables on deposition pattern of nasal spray pumps evaluated using a nasal cast. Pharm. Res. 2011, 28:1895-1904.
60. Landgraf R. Plasma oxytocin concentrations in man after different routes of administration of synthetic oxytocin. Exp. Clin. Endocrinol. 1985, 85:145-148.
61. Littlejohn M.C., Stiernberg C.M., Hokanson J.A., Quinn F.B., Bailey B.J. The relationship between the nasal cycle and mucociliary clearance. Laryngoscope 1992, 102:117-120.
62. Marttin E., Schipper N.G.M., Verhoef J.C., Merkus F.W. Nasal mucociliary clearance as a factor in nasal drug delivery. Adv. Drug Del. Rev. 1998, 29:13-38.
63. Marx D. Selecting a nasal spray pump. Inhalation 2009, 18:18-21.
64. Marx, D., Birkhoff, M., 2011. Multi-dose container for nasal and ophthalmic drugs: a preservative free future? Drug Development - A Case Study Based Insight into Modern Strategies, pp. 509-524.
65. Merkus F.W.H.M., van den Berg M.P. Can nasal drug delivery bypass the blood-brain barrier?: Questioning the direct transport theory. Drugs R. D. 2007, 8:133-144.
66. Merkus P. Current Aspects of Nasal Drug Delivery 2006, University of Amsterdam, Amsterdam, Netherlands.
67. Merkus P., Ebbens F.A., Muller B., Fokkens W.J. The 'best method' of topical nasal drug delivery: comparison of seven techniques. Rhinology 2006, 44:102-107.
68. Merkus P., Ebbens F.A., Muller B., Fokkens W.J. Influence of anatomy and head position on intranasal drug deposition. Rhinology 2006, 263:827-832.
69. Modi M.E., Young L.J. The oxytocin system in drug discovery for autism: Animal models and novel therapeutic strategies. Horm. Behav. 2012, 61:340-350.
70. Mygind N., Anggard A. Anatomy and physiology of the nose--pathophysiologic alterations in allergic rhinitis. Clin. Rev. Allergy 1984, 2:173-188.
71. Mygind N., Vesterhauge S. Aerosol distribution in the nose. Rhinology 1978, 16:79-88.
72. Nance E.A., Woodworth G.F., Sailor K.A., Shih T.-Y., Xu Q., Swaminathan G., Xiang D., Eberhart C., Hanes J. A dense poly(ethylene glycol) coating improves penetration of large polymeric nanoparticles within brain tissue. Sci. Transl. Med. 2012, 4:149ra119.
73. Newman S.P., Moren F., Clarke S.W. Deposition pattern of nasal sprays in man. Rhinology 1988, 26:111-120.
74. Ocskó T., Gálfi M., Radács M., Molnár Z., Kis G.K., Rákosi K., Molnár A.H., László F., László F.A., Varga C. Effects of orexin-monoaminergic interactions on oxytocin secretion in rat neurohypophyseal cell cultures. Regul. Pept. 2012, 175:43-48.
75. Pennington A.K., Ratcliffe J.H., Wilson C.G., Hardy J.G. The influence of solution viscosity on nasal spray deposition and clearance. Int. J. Pharm. 1987, 43:221-224.
76. Perez A.P., Mundina-Weilenmann C., Romero E.L., Morilla M.J. Increased brain radioactivity by intranasal P-labeled siRNA dendriplexes within in situ-forming mucoadhesive gels. Int. J. Nanomed. 2012, 7:1373-1385.
77. PSA Australian Pharmaceutical Formulary 2012, Pharmaceutical Society of Australia, Parkvlle. 22nd ed.
78. Qingfeng L., Yehong S., Jie C., Xiaoling G., Chengcheng F., Lu W., Qizhi Z., Xinguo J. Nose-to-brain transport pathways of wheat germ agglutinin conjugated PEG-PLA nanoparticles. Pharm. Res. 2012, 29:546-558.
79. Riederer A., Fischer A., Knipping S., Unger J., Lange W., Kastenbauer E. Basic innervation pattern and distribution of classic autonomic neurotransmitters in human nasal mucosal vasculature. Laryngoscope 1996, 106:286-291.
80. Roethlisberger F.J., Dickson W.J. Hawthorne and the Western Electric Company 2003, Routledge, London.
81. Romero E.L., Morilla M.J. Topical and mucosal liposomes for vaccine delivery. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2011, 3:356-375.
82. Ruis, H., Rolland, R., Doesburg, W., Broeders, G., Corbey, R., 1981. Oxytocin enhances onset of lactation among mothers delivering prematurely, 283, 340-342.
83. Rupp C.I. Reduced olfactory sensitivity, discrimination, and identification in patients with alcohol dependence. Alcohol Clin. Exp. Res. 2003, 27:432.
84. Sakakura Y., Ukai K., Majima Y., Murai S., Harada T., Miyoshi Y. Nasal mucociliary clearance under various conditions. Acta Otolaryngol. 1983, 96:167-173.
85. Samolin B.K., Grzanka A., Gotlib T. Changes in nasal cavity dimensions in children and adults by gender and age. Laryngoscope 2007, 117:1429-1433.
86. Scheibe M., Bethge C., Witt M., Hummel T. Intranasal administration of drugs. Arch. Otolaryngol. Head Neck Surg. 2008, 134:643-646.
87. Schipper N.G., Verhoef J.C., Merkus F.W. Nasal mucociliary clearance: relevance to nasal drug delivery. Pharm. Res. 1991, 8:807-814.
88. Schroeter J.D., Garcia G.J.M., Kimbell J.S. Effects of surface smoothness on inertial particle deposition in human nasal models. J. Aerosol. Sci. 2011, 42:52-63.
89. Schubert C.R., Cruickshanks K.J., Klein B.E., Klein R., Nondahl D.M. Olfactory impairment in older adults: five-year incidence and risk factors. Laryngoscope 2011, 121:873-878.
90. Schumacher M.J. Nasal congestion and airway obstruction: the validity of available objective and subjective measures. Curr. Allergy Asthma Rep. 2002, 2:245-251.
91. Smith S., Edwards P.C., Saini T.S., Norton N.S. The prevalence of concha bullosa and nasal septal deviation and their relationship to maxillary sinusitis by volumetric tomography. Int. J. Dent. 2010, 1-5.
92. Southall J., Ellis C. Development in nasal drug delivery. Innov. Pharm. Technol. 2000.
93. Stephens L.C., Bruessel T. Systematic review of oxytocin dosing at caesarean section. Anaesth. Intensive Care 2012, 40:247-252.
94. Stevens J., Ploeger B.A., van der Graaf P.H., Danhof M., de Lange E.C.M. Systemic and direct nose-to-brain transport pharmacokinetic model for remoxipride after intravenous and intranasal administration. Drug Metab. Disp. 2011, 39:2275-2282.
95. Suman J.D., Laube B.L., Dalby R. Comparison of nasal deposition and clearance of aerosol generated by nebulizer and an aqueous spray pump. Pharm. Res. 1999, 16:1648-1652.
96. Suter-Zimmermann, K., 2008. Transmucosal nasal drug delivery: systemic bioavailability of nasally applied midazolam (Unpublished PhD Thesis). Faculty of Sciences. University of Basel, Basel, Switzerland.
97. Szücs E., Clement P.A.R. Acoustic rhinometry and rhinomanometry in the evaluation of nasal patency of patients with nasal deptal deviation Am. J. Rhinol. 1998, 12:345-352.
98. Thorne R.G., Pronk G.J., Padmanabhan V., Frey W.H. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 2004, 127:481-496.
99. Trimarchi M., Nicolai P., Lombardi D., Facchetti F., Morassi M.L., Maroldi R., Gregorini G., Specks U. Sinonasal osteocartilaginous necrosis in cocaine abusers: experience in 25 patients. Am. J. Rhinol. 2003, 17:33-43.
100. Turker S., Onur E., Ozer Y. Nasal route and drug delivery systems. Pharm. World Sci. 2004, 26:137-142.
101. van Spronsen E., Ingels K.J., Jansen A.H., Graamans K., Fokkens W.J. Evidence-based recommendations regarding the differential diagnosis and assessment of nasal congestion: using the new GRADE system. Allergy 2008, 63:820-833.
102. Vidgren M.T., Kublik H. Nasal delivery systems and their effect on deposition and absorption. Adv. Drug Deliv. Rev. 1998, 29:157-177.
103. Vyas T.K., Babbar A.K., Sharma R.K., Singh S., Misra A. Intranasal mucoadhesive microemulsions of clonazepam: preliminiary studies on brain targeting. J. Pharm. Sci. 2006, 95:570-580.
104. Weber R., Keerl R., Radziwill R., Schick B., Jaspersen D., Dshambazov K., Mlynski G., Draf W. Videoendoscopic analysis of nasal steroid distribution. Rhinology 1999, 37:69-73.
105. Weller R., Galea I., Carare R., Minagar A. Pathophysiology of the lymphatic drainage of the central nervous system: implications for pathogenesis and therapy of multiple sclerosis. Pathophysiology 2010, 17:295-306.
106. Wermeling D.P. Intranasal delivery of antiepileptic medications for treatment of seizures. Neurotherapeutics 2009, 6:352-358.
107. Wheeler S.M., Corey J.P. Evaluation of upper airway obstruction-an ENT perspective. Pulm. Pharmacol. Ther. 2008, 21:433-441.
108. Widdicombe J. The airway vasculature. Exp. Physiol. 1993, 78:433-452.
109. Xia H., Gao X., Gu G., Liu Z., Zeng N., Hu Q., Song Q., Yao L., Pang Z., Jiang X., Chen J., Chen H. Low molecular weight protamine-functionalized nanoparticles for drug delivery to the brain after intranasal administration. Biomaterials 2011, 32:9888-9898.
110. Yergin B.M., Saketkhoo K., Michaelson E.D., Serafini S.M., Kovitz K., Sackner M.A. A roentgenographic method for measuring nasal mucous velocity. J. Appl. Physiol. 1978, 44:964-968.
111. Young L.J., Wang Z. The neurobiology of pair bonding. Nat. Neurosci. 2004, 7:1048-1054.
112. Zempsky W.T. Alternative routes of drug administration-advantages and disadvantages. Pediatrics 1998, 100:143-152.
113. Zhao K., Scherer P.W., Hajiloo S.A., Dalton P. Effect of anatomy on human nasal air flow and odorant transport patterns: implications for olfaction. Chem. Sens. 2004, 29:365-379.